MGT-1142 / Marigold Therapeutics - LARVOL DELTA

MGT-1142, an antibody-drug conjugate targeting a novel glycan for small-cell lung cancer (AACR 2026) - "MGT-1142 shows potent and selective anti-tumor activity, favorable pharmacokinetics, and an encouraging safety profile in preclinical studies. These findings support MGT-1142 as a potential first-in-class glycan-targeting ADC for the treatment of small-cell lung cancer."

ADC • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor